The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer.
Victor HF Lee
Honoraria - Lilly
Weijia Fang
No relevant relationships to disclose
Ka On Lam
No relevant relationships to disclose
Cheuk Wai Choi
No relevant relationships to disclose
Sherry CY Ng
No relevant relationships to disclose
Patty PY Ho
No relevant relationships to disclose
Garrett CL Ho
No relevant relationships to disclose
Thomas KC Cheng
No relevant relationships to disclose
Rico KY Liu
No relevant relationships to disclose
To Wai Leung
No relevant relationships to disclose
Dora Lai Wan Kwong
No relevant relationships to disclose
Shusen Zheng
No relevant relationships to disclose